Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice

Supportive Care in Cancer

Volumn 20, Issue 5, 2012, Pages 941-949

  Hatoum, Hind T ^a,b   Lin, Swu Jane ^a,b   Buchner, Deborah ^c   Cox, David ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Hind T Hatoum and Company   (United States)

^c EISAI INC   (United States)

Author keywords

5 HT 3 RAs; CINV; Comparative effectiveness; Palonosetron

Indexed keywords

APREPITANT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST;

ADJUVANT THERAPY; ADULT; AGE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COHORT ANALYSIS; COMORBIDITY; DEHYDRATION; DRUG EFFICACY; EMERGENCY WARD; FEMALE; GENDER; HOSPITAL ADMISSION; HUMAN; ICD-9; LUNG CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NAUSEA; PRIORITY JOURNAL; PROBABILITY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARBOPLATIN; CISPLATIN; COHORT STUDIES; CYCLOPHOSPHAMIDE; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; ISOQUINOLINES; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; QUINUCLIDINES; RETROSPECTIVE STUDIES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 84863446648     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1165-1     Document Type: Review

References (21)

1. Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21:1373-1378. doi:10-1200/ JCO.2003-08.118
2. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441-1449. doi:10-1093/annonc/mdl137
3. Oo TH, Hesketh PJ (2005) Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol 2:196-201. doi:10-1038/ncponc0132
4. Li Y, Wu X, Rojas C (2009) Palonosetron uniquely inhibits substance P-mediated neuronal responses in rat nodose ganglia. Annual American Society of Hematology Meeting, New Orleans
5. Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, Sebastiani S, Cantoreggi S, Slusher BS (2010) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626:193-199. doi:10-1016/j.ejphar.2009-10.002
6. Siddiqui MA, Scott LJ (2004) Palonosetron. Drugs 64:1125-1132. doi:10-2165/00003495-200464100-00006
7. Yang LP, Scott LJ (2009) Palonosetron: in the prevention of nausea and vomiting. Drugs 69:2257-2278. doi:10-2165/ 11200980-000000000-00000
8. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577. doi:10-1093/annonc/mdg417
9. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473-2482. doi:10-1002/cncr.11817
10. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115-124. doi:10-1016/S1470-2045(08)70313-9
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373-383
12. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130-1139. doi:10-1097/01. mlr.0000182534-19832.83
13. Zhang J, Yu KF (1998) What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280:1690-1691. doi:10-1001/jama.280-19.1690
14. Yeh YC, McDonnell A, Klinger EV, Fowler B, Matta L, Voit D, Reddy P (2011) Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract. doi:10-1177/1078155210366491
15. Perez E, Muss HB (2005) Optimizing adjuvant chemotherapy in early-stage breast cancer. Oncology 19:1759-1767
16. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P (2005) 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330:217. doi:10-1136/bmj.38314-622095. 8F
17. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V (2006) Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 4:403-408
18. Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M (2009) Effectiveness of a single-day threedrug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Canc 17:589-594
19. Herrington JD, Jaskiewicz AD, Song J (2008) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112(9):2080-2087
20. Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D. Risk of uncontrolled chemotherapy induced nausea and vomiting (CINV) with highly emetogenic chemotherapy and a triple combination anti-emetic prophylaxis regimen. Abtract accepted at 2011 Hematology/Oncology Pharmacists Association Annual Meeting; March 23-26, Salt Lake City, Utah
21. Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A (2007) Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? J Oncol Pharm Pract 13:69-75. doi:10-1177/1078155207078137